全文获取类型
收费全文 | 290篇 |
免费 | 16篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 1篇 |
基础医学 | 22篇 |
临床医学 | 10篇 |
内科学 | 25篇 |
神经病学 | 215篇 |
特种医学 | 11篇 |
外科学 | 4篇 |
综合类 | 1篇 |
预防医学 | 5篇 |
眼科学 | 5篇 |
药学 | 5篇 |
肿瘤学 | 2篇 |
出版年
2023年 | 3篇 |
2021年 | 6篇 |
2020年 | 7篇 |
2019年 | 6篇 |
2018年 | 5篇 |
2017年 | 8篇 |
2016年 | 5篇 |
2015年 | 8篇 |
2014年 | 11篇 |
2013年 | 8篇 |
2012年 | 26篇 |
2011年 | 25篇 |
2010年 | 10篇 |
2009年 | 12篇 |
2008年 | 15篇 |
2007年 | 20篇 |
2006年 | 16篇 |
2005年 | 22篇 |
2004年 | 11篇 |
2003年 | 14篇 |
2002年 | 5篇 |
2001年 | 7篇 |
2000年 | 11篇 |
1999年 | 6篇 |
1998年 | 1篇 |
1997年 | 2篇 |
1996年 | 3篇 |
1995年 | 4篇 |
1993年 | 1篇 |
1992年 | 5篇 |
1991年 | 1篇 |
1990年 | 9篇 |
1989年 | 4篇 |
1988年 | 4篇 |
1987年 | 2篇 |
1986年 | 2篇 |
1985年 | 1篇 |
1982年 | 1篇 |
排序方式: 共有307条查询结果,搜索用时 15 毫秒
91.
Confavreux C Vukusic S Arbizu T Brochet B Clanet M Edan G Kappos L Suissa S 《Revue neurologique》2005,161(6-7):644-6; author reply 646-7
92.
There are presently many magnetic resonance (MR) measures that can aid the assessment of damage to the brain. The conventional measures include T2 lesion volume, T1 enhanced lesion volume, and brain atrophy. Newer methodologies include magnetization transfer measures and proton spectroscopy. These methods have the potential for improving the specificity of MR with respect to the underlying pathology. MR spectroscopy offers the ability to quantitate the component of axonal loss in multiple sclerosis. MR techniques can be implemented to assess the effectiveness of treatment algorithms. 相似文献
93.
Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study 总被引:15,自引:0,他引:15
Fassas A Passweg JR Anagnostopoulos A Kazis A Kozak T Havrdova E Carreras E Graus F Kashyap A Openshaw H Schipperus M Deconinck E Mancardi G Marmont A Hansz J Rabusin M Zuazu Nagore FJ Besalduch J Dentamaro T Fouillard L Hertenstein B La Nasa G Musso M Papineschi F Rowe JM Saccardi R Steck A Kappos L Gratwohl A Tyndall A Samijn J Samign J;Autoimmune Disease Working Party of the EBMT 《Journal of neurology》2002,249(8):1088-1097
Rationale Phase I/II studies of autologous hematopoietic stem cell transplantation (HSCT) for multiple sclerosis (MS) were initiated, based on results of experimental transplantation in animal models of multiple sclerosis and clinical observations
in patients treated concomitantly for malignant disease. Patients Eighty-five patients with progressive MS were treated with autologous HSCT in 20 centers and reported to the autoimmune disease working party of the European Group
for Blood and Marrow Transplantation (EBMT). 52 (61 %) were female, median age was 39 [20-58] years. The median interval from
diagnosis to transplant was 7 [1-26] years. Patients suffered from severe disease with a median EDSS score of 6.5 [4.5-8.5].
Active disease prior to transplant was documented in 79 of 82 evaluable cases. Results The stem cell source was bone marrow in 6 and peripheral blood in 79, and stem cells were mobilized into peripheral blood
using either cyclophosphamide combined with growth factors or growth factors alone. Three patients experienced transient neurological
complications during the mobilization phase. The high dose regimen included combination chemotherapy, with or without anti-lymphocyte
antibodies or, with or without, total body irradiation. The stem cell transplants were purged of lymphocytes in 52 patients.
Median follow-up was 16 [3-59] months. There were 7 deaths, 5 due to toxicity and infectious complications, 2 with neurological
deterioration. The risk of death of any cause at 3 years was 10 (±7)% (95 % confidence interval). Neurological deterioration
during transplant was observed in 22 patients; this was transient in most but was associated with MS progression in 6 patients.
Neurological improvement by ≥ 1 point in the EDSS score was seen in 18 (21 %) patients. Confirmed progression-free survival
was 74 (±12)% at 3 years being 66 (±23)% in patients with primary progressive MS but higher in patients with secondary progressive
or relapsing-remitting MS, 78 (±13)%; p = 0.59. The probability of confirmed disease progression was 20 (±11)%. MRI data were
available in 78 patients before transplant showing disease activity (gadolinium enhancing, new or enlarging lesions) in 33
%. Posttransplant MRI showed activity at any time in 5/61 (8 %) evaluable cases. Conclusion Autologous HSCT suggest positive early results in the management of progressive MS and is feasible. These multicentre data
suggest an association with significant mortality risks especially in some patient groups and are being utilised in the planning
of future trials to reduce transplant related mortality.
Received: 21 August 2001 Received in revised form: 4 February 2002 Accepted: 6 February 2002 相似文献
94.
95.
96.
H Klepzig M Aumüller J Kreuzer C Baldamus E Krause A D Kappos M Kaltenbach 《Zeitschrift für Kardiologie》1985,74(2):130-131
We report on a 54-year-old patient with chronic renal failure, in whom complete AV block occurred after aortic valve replacement. During hemofiltration an external demand pacemaker sensed spikes induced by the employed machine. This caused an asystole. Fixed rate pacing re-established regular ventricular contractions. 相似文献
97.
Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. 总被引:20,自引:16,他引:4
下载免费PDF全文
![点击此处可从《Journal of neurology, neurosurgery, and psychiatry》网站下载免费的PDF全文](/ch/ext_images/free.gif)
D H Miller F Barkhof I Berry L Kappos G Scotti A J Thompson 《Journal of neurology, neurosurgery, and psychiatry》1991,54(8):683-688
Serial gadolinium enhanced MRI of the brain detects much clinically silent disease activity in early relapsing-remitting and secondary progressive multiple sclerosis (MS), and thus has an important role in monitoring the effects of therapy. Based on the proceedings of a recent Commission of the European Communities (CEC) workshop and a review of the literature, guidelines are presented for using MRI to monitor treatment trials in MS. The guidelines consider: A) MRI system and techniques; B) patient selection; C) trial design; D) analysis of results. Priorities for future research are also indicated. 相似文献
98.
Rüegg S Lehky Hagen M Hohl U Kappos L Fuhr P Plasilov M Müller H Heinimann K 《Swiss medical weekly》2005,135(39-40):574-586
Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant muscle disorder, usually of late onset. OPMD is among the few triplet repeat diseases/ polyalanine (poly(A)) expansion diseases for which the function of the mutated gene is quite well established. The disease is characterised by slowly progressive bilateral ptosis, dysphagia and proximal limb weakness, appearing after the age of 40 years. Prevalence and incidence of OPMD are low, but the disease occurs all over the world. The pedigrees of two Swiss kindred have been previously reported in Switzerland. In the last 2 years, accumulation of newly diagnosed cases in North-West Switzerland have been observed, which suggests that OPMD may be more prevalent than previously thought. Primary care providers, opthalmologists and neurologists that are alert for the almost specific combination of clinical signs, together with the availability of reliable genetic testing may help to recognise currently undiagnosed patients. They can advance knowledge and the characterisation of the OPMD population in Switzerland. Since the number of disorders linked to poly(A) expansions is growing rapidly, the study of OPMD may contribute to the understanding of a large group of other developmental and degenerative diseases. On the basis of a patient with "classical" OPMD, this review summarises the clinical, therapeutic, epidemiological, pathomechanistic and genetic aspects of OPMD, provides practical information about the differential diagnosis of OPMD, and presents a survey of different investigational methods. 相似文献
99.
Hardmeier M Wagenpfeil S Freitag P Fisher E Rudick RA Kooijmans-Coutinho M Clanet M Radue EW Kappos L;European rIFN beta-a in Relapsing MS Dose Comparison Trial Study Group 《Archives of neurology》2003,60(12):1736-1739
BACKGROUND: Atrophy is recognized as a measure of destructive changes in multiple sclerosis (MS). The time course and pathologic mechanisms of atrophy development are not well understood. Significant atrophy was reported to occur within 9 to 12 months in relapsing remitting MS. OBJECTIVES: To test whether atrophy can be detected over short time intervals, and to evaluate its relationship to inflammation.Design and METHODS: Prior to randomization to a treatment trial, 138 untreated patients with relapsing remitting MS had 3 magnetic resonance imaging scans within a mean +/- SD follow-up of 76 +/- 20.2 days. Brain parenchymal fraction (BPF), a normalized measure of whole brain volume, the proportion of active (gadolinium-enhancing) scans, and the volume of T1-weighted gadolinium-enhancing and T2-weighted hyperintense lesions were determined at all time points. An annualized atrophy rate was estimated by calculating a regression slope. RESULTS: The median Expanded Disability Status Scale score was 3.5, the mean disease duration was 7.6, and the mean age was 38.5 years. The BPF decreased significantly by -0.229% from scan 1 to scan 3, while the proportion of active scans remained high (65%, 63%, and 67%). The BPF change was only weakly correlated to the volume of T1-weighted gadolinium-enhancing lesions in scan 1 (r = -0.185). The estimated annualized atrophy rate was -1.06% (95% confidence interval, -1.50% to -0.62%). CONCLUSIONS: The annualized atrophy rate found in this study is comparable with rates reported previously. Measurements of BPF allow detection of atrophy over short time intervals in active disease. The short-term relationship of inflammation to atrophy development was weak. Brain parenchymal fraction might be a promising measure in future phase 2 studies of agents, with an expected effect on tissue-destructive pathologic mechanisms of MS. 相似文献
100.
The increasing use of magnetic resonance imaging (MRI) as a diagnostic tool for multiple sclerosis (MS) as recently enforced in the McDonald committee criteria--and the importance of MRI measurements in therapeutic studies both demonstrate the value of MRI findings. MRI aids our understanding of MS and management of patients. 相似文献